SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630
  • 2
    Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S6S
  • 3
    Demetri GD, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 47280
  • 4
    Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 10317
  • 5
    Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 216372
  • 6
    Tory K, Brauch H, Linehan M et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989; 81: 1097101
  • 7
    Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 131720
  • 8
    Linehan WM, Vasselli J, Srinivasan R et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10: 6282S9S
  • 9
    Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 8590
  • 10
    Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 97004
  • 11
    Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 45939
  • 12
    Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 84350
  • 13
    Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 8516
  • 14
    Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 42734
  • 15
    Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1624
  • 16
    Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 250512
  • 17
    Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989; 320: 12112
  • 18
    Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208: 5168
  • 19
    Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 45626
  • 20
    Von Marschall MZ, Scholz A, Cramer T et al. Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 43748
  • 21
    Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10: 25846
  • 22
    Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 788996
  • 23
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 253040
  • 24
    Bukowski R, Kabbinavar F, Figlin R et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 2006; 24 (Suppl.): 18s
  • 25
    Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 1227
  • 26
    Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24 (Suppl): 18S
  • 27
    De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma (1). Acad Radiol 2005; 12: 34757
  • 28
    De Bazelaire C, Alsop D, Rofsky N et al. MRI-measured tumor blood flow change following treatment with PTK/ZK correlates with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 14, 2003
  • 29
    George D, Michaelson D, Oh W et al. Phase I study of PTK787/ZK 222584 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003 (abstract 1648)
  • 30
    O’Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43–9006 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2005 (abstract 3005)
  • 31
    Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 3552